B
Baptiste Ronan
Researcher at Aventis Pharma
Publications - 55
Citations - 435
Baptiste Ronan is an academic researcher from Aventis Pharma. The author has contributed to research in topics: Alkyl & Alkoxy group. The author has an hindex of 10, co-authored 55 publications receiving 431 citations. Previous affiliations of Baptiste Ronan include University of Paris-Sud & Sanofi S.A..
Papers
More filters
Journal ArticleDOI
From PtCl2‐ and Acid‐Catalyzed to Uncatalyzed Cycloisomerization of 2‐Propargyl Anilines: Access to Functionalized Indoles
Journal ArticleDOI
Highly diastereoselective Diels-Alder reactions with (R)-ethoxy p-tolyl vinyl sulfonium tetrafluoroborate
Baptiste Ronan,Henri B. Kagan +1 more
TL;DR: In this article, a Tolyl vinyl sulfoxide has been efficiently activated for Diels-Alder reactions by transformation into a sulfonium salt 3a or by addition of TMSOTf.
Patent
7-substituted aza-indazoles, compositions containing same, production method and use thereof
Bjergarde Kirsten,Anil Nair,Marcel Patek,Dodson Mark,Martha Ackerman-Berrier,Martin Smrcina,Vincent Leroy,Bacque Eric,Michel Tabart,Baptiste Ronan,Fabrice Viviani,Catherine Souaille +11 more
TL;DR: The 7-aza-indazoles having formula (I) as mentioned in this paper modulate the activity of proteins, particularly kinases, compositions containing same and the use thereof as a medicament, in particular as anticancer agents.
Journal ArticleDOI
Highly enantioselective synthesis of a Corey prostaglandin intermediate
Baptiste Ronan,Henri B. Kagan +1 more
TL;DR: In this paper, a (R)-p-tolyl vinyl sulfoxide was transformed into the corresponding ethoxysulfonium compound, which smoothly underwent reaction with 5-benzyloxymethyl-1,3-cyclopentadiene to give, after basic treatment, the bicyclic sulfoxide10 with very high de.
Patent
N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris
Kleemann Heinz-Werner,Armin Hofmeister,Carry Jean-Christophe,Serge Mignani,Antony Bigot,Baptiste Ronan +5 more
TL;DR: In this paper, the authors describe the use of isoindolone derivatives of the Formula (I) as antiarrhythmic medicaments with a cardioprotective component for infarrction prophylaxis and infarction treatment.